# ALNY — Alnylam Pharmaceuticals Inc · catalysts, narrative & risks

**Deep-research report — K3vl4r**  
**Symbols:** ALNY  
**Sources:** 56  
**Published:** 2026-07-30  
**Canonical:** https://app.k3vl4r.com/research/deep-research-alny-alnylam-pharmaceuticals-inc-catalysts-narrative-ris-593

---

**Executive Summary**  
As of 30 July 2026, Alnylam Pharmaceuticals (ticker ALNY) remains a differentiated leader in the RNA‑i space, with a robust pipeline that spans cardiovascular, neurologic, and metabolic disorders. The company’s stock closed at $312.79 on 3 July 2026 [[1]](https://finance.yahoo.com/quote/ALNY/) and has since posted a 6.3 % gain following its second‑quarter earnings announcement on 14 July 2026 [[13]](https://www.quiverquant.com/news/Alnylam+Rises+as+Investors+Weigh+Pipeline+Momentum,+Earnings+Setup,+and+ATTR-CM+Positioning). Analysts have adjusted price targets (H.C. Wainwright and TipRanks) and reaffirmed a “Buy” rating, citing the firm’s progress in Phase III trials, upcoming manufacturing investment, and regulatory milestones [[10]](https://www.cnn.com/markets/stocks/ALNY), [[12]](https://www.cnbc.com/quotes/ALNY).  

---

## 1. Key RECENT Catalysts (Last ~1–3 Months)

---

_Preview only. The complete multi-source deep-research report — full thesis, evidence, and citations — is available at https://app.k3vl4r.com/research/deep-research-alny-alnylam-pharmaceuticals-inc-catalysts-narrative-ris-593 (free to sign up)._